{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T19:30:51Z","timestamp":1783625451780,"version":"3.55.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s11899-020-00560-x","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T06:15:00Z","timestamp":1582179300000},"page":"20-30","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia"],"prefix":"10.1007","volume":"15","author":[{"given":"Dakota","family":"Gustafson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason E.","family":"Fish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"Aghel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"issue":"2","key":"560_CR1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00277-015-2314-2","volume":"94","author":"M H\u00f6glund","year":"2015","unstructured":"H\u00f6glund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukemia: an update. Ann Hematol. 2015;94(2):241\u20137.","journal-title":"Ann Hematol"},{"issue":"12","key":"560_CR2","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","volume":"118","author":"X Huang","year":"2012","unstructured":"Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012;118(12):3123\u20137.","journal-title":"Cancer"},{"key":"560_CR3","doi-asserted-by":"publisher","unstructured":"Foulon S, Cony-Makhoul P, Guerci-Bresler A, et al. Using healthcare claims data to analyze the prevalence of BCR-ABL-positive chronic myeloid leukemia in France: A nationwide population-based study. Cancer Med. 2019;8(6):3296\u20133304. https:\/\/doi.org\/10.1002\/cam4.2200.","DOI":"10.1002\/cam4.2200"},{"issue":"1","key":"560_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","volume":"126","author":"Susanne Sau\u00dfele","year":"2015","unstructured":"Saussele S, Krauss MP, Hehlmann R, et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood. 2015;126(1):42\u201349. https:\/\/doi.org\/10.1182\/blood-2015-01-617993.","journal-title":"Blood"},{"issue":"5","key":"560_CR5","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","volume":"17","author":"Jeffrey H Lipton","year":"2016","unstructured":"Lipton JH, Chuah C, Guerci-Bresler A, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(5):612\u2013621. https:\/\/doi.org\/10.1016\/S1470-2045(16)00080-2.","journal-title":"The Lancet Oncology"},{"issue":"35","key":"560_CR6","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","volume":"33","author":"Javid J. Moslehi","year":"2015","unstructured":"Moslehi JJ, Deininger M. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. J Clin Oncol. 2015;33(35):4210\u20134218. https:\/\/doi.org\/10.1200\/JCO.2015.62.4718.","journal-title":"Journal of Clinical Oncology"},{"key":"560_CR7","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2147\/VHRM.S108874","volume":"13","author":"N Aghel","year":"2017","unstructured":"Aghel N, Delgado DH, Lipton JH. Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance. Vasc Health Risk Manag. 2017;13:293.","journal-title":"Vasc Health Risk Manag"},{"issue":"6","key":"560_CR8","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/leu.2015.73","volume":"29","author":"V S Hoffmann","year":"2015","unstructured":"Hoffmann VS, Baccarani M, Hasford J, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia. 2015;29(6):1336\u20131343. https:\/\/doi.org\/10.1038\/leu.2015.73.","journal-title":"Leukemia"},{"issue":"20","key":"560_CR9","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood."},{"key":"560_CR10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/B978-0-323-05594-9.00005-2","volume-title":"Pathology secrets","author":"I Damjanov","year":"2009","unstructured":"Damjanov I. Chapter 5 - Neoplasia. In: Damjanov I, editor. Pathology secrets. 3rd ed. Philadelphia: Mosby; 2009. p. 76\u201397.","edition":"3"},{"key":"560_CR11","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.clml.2015.02.035","volume":"15","author":"S Soverini","year":"2015","unstructured":"Soverini S, de Benedittis C, Mancini M, Martinelli G. Mutations in the BCR-ABL1 kinase domain and elsewhere in chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015;15:S120\u2013S8.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"560_CR12","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1159\/000140633","volume":"119","author":"JM Goldman","year":"2008","unstructured":"Goldman JM, Melo JV. BCR-ABL in chronic myelogenous leukemia--how does it work? Acta Haematol. 2008;119(4):212\u20137. https:\/\/doi.org\/10.1159\/000140633.","journal-title":"Acta Haematol"},{"issue":"2","key":"560_CR13","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1056\/NEJMra044389","volume":"353","author":"DS Krause","year":"2005","unstructured":"Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353(2):172\u201387. https:\/\/doi.org\/10.1056\/NEJMra044389.","journal-title":"N Engl J Med"},{"issue":"2","key":"560_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/s0092-8674(00)00114-8","volume":"103","author":"Joseph Schlessinger","year":"2000","unstructured":"Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103(2):211\u2013225. https:\/\/doi.org\/10.1016\/s0092-8674(00)00114-8.","journal-title":"Cell"},{"issue":"3","key":"560_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3109\/10408363.2013.874403","volume":"51","author":"E Gocek","year":"2014","unstructured":"Gocek E, Moulas AN, Studzinski GP. Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells. Crit Rev Clin Lab Sci. 2014;51(3):125\u201337. https:\/\/doi.org\/10.3109\/10408363.2013.874403.","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"139","key":"560_CR16","doi-asserted-by":"publisher","first-page":"re6-re","DOI":"10.1126\/scisignal.3139re6","volume":"3","author":"J Colicelli","year":"2010","unstructured":"Colicelli J. ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci Signal. 2010;3(139):re6-re. https:\/\/doi.org\/10.1126\/scisignal.3139re6.","journal-title":"Sci Signal"},{"issue":"4944","key":"560_CR17","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science. 1990;247(4944):824\u201330.","journal-title":"Science"},{"issue":"3","key":"560_CR18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren R. Mechanisms of BCR\u2013ABL in the pathogenesis of chronic myelogenous leukemia. Nat Rev Cancer. 2005;5(3):172\u201383. https:\/\/doi.org\/10.1038\/nrc1567.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"560_CR19","first-page":"2049","volume":"60","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Vieira S, Mendiola R, Schultheis B, Goldman JM, Melo JV. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res. 2000;60(7):2049\u201355.","journal-title":"Cancer Res"},{"issue":"S2","key":"560_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00277-015-2325-z","volume":"94","author":"Bradley Chereda","year":"2015","unstructured":"Chereda B, Melo JV. Natural course and biology of CML. Ann Hematol. 2015;94 Suppl 2:S107\u2013S121. https:\/\/doi.org\/10.1007\/s00277-015-2325-z.","journal-title":"Annals of Hematology"},{"key":"560_CR21","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/j.clml.2015.02.012","volume":"15","author":"CT Dalg\u0131\u00e7","year":"2015","unstructured":"Dalg\u0131\u00e7 CT, Kaymaz BT, \u00d6zkan MC, Dalm\u0131zrak A, \u015eahin F, Saydam G, et al. Investigating the role of JAK\/STAT pathway on dasatinib-induced apoptosis for CML cell model K562. Clin Lymphoma Myeloma Leuk. 2015;15:S161\u2013S6.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"560_CR22","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/jcb.25559","volume":"117","author":"S Dinner","year":"2016","unstructured":"Dinner S, Platanias LC. Targeting the mTOR pathway in leukemia. J Cell Biochem. 2016;117(8):1745\u201352.","journal-title":"J Cell Biochem"},{"issue":"6","key":"560_CR23","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s13402-015-0248-2","volume":"38","author":"J Bertacchini","year":"2015","unstructured":"Bertacchini J, Ketabchi N, Mediani L, Capitani S, Marmiroli S, Saki N. Inhibition of Ras-mediated signaling pathways in CML stem cells. Cell Oncol (Dordr). 2015;38(6):407\u201318.","journal-title":"Cell Oncol (Dordr)"},{"issue":"21","key":"560_CR24","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1158\/1078-0432.Ccr-10-1638","volume":"16","author":"DH Kim","year":"2010","unstructured":"Kim DH, Kong JH, Byeun JY, Jung CW, Xu W, Liu X, et al. The IFNG (IFN-\u03b3) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res. 2010;16(21):5339\u201350. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-10-1638.","journal-title":"Clin Cancer Res"},{"issue":"5205","key":"560_CR25","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1126\/science.7892601","volume":"267","author":"A Levitzki","year":"1995","unstructured":"Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science. 1995;267(5205):1782\u20138.","journal-title":"Science"},{"issue":"24","key":"560_CR26","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/jco.2015.66.2866","volume":"34","author":"Hannah Bower","year":"2016","unstructured":"\u2022\u2022 Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851\u20137. https:\/\/doi.org\/10.1200\/jco.2015.66.2866. Critical analysis of the long-term effects of tyrosine-kinase inhibitors and their effect on life expectancy.","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"560_CR27","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","volume":"122","author":"Martin H\u00f6glund","year":"2013","unstructured":"Hoglund M, Sandin F, Hellstrom K, Bjoreman M, Bjorkholm M, Brune M, et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood. 2013;122(7):1284\u201392. https:\/\/doi.org\/10.1182\/blood-2013-04-495598.","journal-title":"Blood"},{"issue":"12","key":"560_CR28","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.3109\/10428194.2012.695779","volume":"53","author":"JL Steegmann","year":"2012","unstructured":"Steegmann JL, Cervantes F, le Coutre P, Porkka K, Saglio G. Off-target effects of BCR\u2013ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leuk Lymphoma. 2012;53(12):2351\u201361.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"560_CR29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nbt1358","volume":"26","author":"Mazen W Karaman","year":"2008","unstructured":"Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26(1):127\u2013132. https:\/\/doi.org\/10.1038\/nbt1358.","journal-title":"Nature Biotechnology"},{"issue":"2","key":"560_CR30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00277-015-2318-y","volume":"94","author":"D Rea","year":"2015","unstructured":"Rea D. Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Ann Hematol. 2015;94(2):149\u201358.","journal-title":"Ann Hematol"},{"issue":"5","key":"560_CR31","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nrc2106","volume":"7","author":"T Force","year":"2007","unstructured":"Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7(5):332.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"560_CR32","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.leukres.2010.01.004","volume":"34","author":"A Wolf","year":"2010","unstructured":"Wolf A, Couttet P, Dong M, Grenet O, Heron M, Junker U, et al. Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies. Leuk Res. 2010;34(9):1180\u20138. https:\/\/doi.org\/10.1016\/j.leukres.2010.01.004.","journal-title":"Leuk Res"},{"issue":"19","key":"560_CR33","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/blood-2012-02-410688","volume":"120","author":"JP Radich","year":"2012","unstructured":"Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, et al. A randomized trial of dasatinib 100\u00a0mg versus imatinib 400\u00a0mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012;120(19):3898\u2013905.","journal-title":"Blood."},{"issue":"1","key":"560_CR34","doi-asserted-by":"publisher","first-page":"1700217","DOI":"10.1183\/13993003.00217-2017","volume":"50","author":"Jason Weatherald","year":"2017","unstructured":"Weatherald J, Chaumais MC, Savale L, et al. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. Eur Respir J. 2017;50(1):1700217. Published 2017 Jul 27. https:\/\/doi.org\/10.1183\/13993003.00217-2017.","journal-title":"European Respiratory Journal"},{"issue":"20","key":"560_CR35","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"Jorge E. Cortes","year":"2016","unstructured":"\u2022 Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333. Critical analysis of the effects of dasatinib compared to imatinib in treatment-naive patients.","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"560_CR36","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1016\/S2352-3026(15)00021-6","volume":"2","author":"P Jain","year":"2015","unstructured":"Jain P, Kantarjian H, Alattar ML, Jabbour E, Sasaki K, Gonzalez GN, et al. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400\u00a0mg, imatinib 800\u00a0mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukemia: retrospective analysis of patient data from five clinical trials. Lancet Hematol. 2015;2(3):e118\u2013e28.","journal-title":"Lancet Hematol"},{"issue":"5","key":"560_CR37","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044\u20131054. https:\/\/doi.org\/10.1038\/leu.2016.5.","journal-title":"Leukemia"},{"issue":"5","key":"560_CR38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.clml.2012.04.005","volume":"12","author":"A Quint\u00e1s-Cardama","year":"2012","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk. 2012;12(5):337\u201340.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"560_CR39","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/blood-2013-07-513937","volume":"123","author":"HM Kantarjian","year":"2014","unstructured":"Kantarjian HM, Cortes JE, Kim D-W, Khoury HJ, Br\u00fcmmendorf TH, Porkka K, et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood. 2014;123(9):1309\u201318.","journal-title":"Blood."},{"issue":"28","key":"560_CR40","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/jco.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kim DW, Kantarjian HM, Brummendorf TH, Dyagil I, Griskevicius L, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30(28):3486\u201392. https:\/\/doi.org\/10.1200\/jco.2011.38.7522.","journal-title":"J Clin Oncol"},{"issue":"4","key":"560_CR41","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00277-016-2820-x","volume":"96","author":"M Breccia","year":"2017","unstructured":"Breccia M, Pregno P, Spallarossa P, Arboscello E, Ciceri F, Giorgi M, et al. Identification, prevention and management of cardiovascular risk in chronic myeloid leukemia patients candidate to ponatinib: an expert opinion. Ann Hematol. 2017;96(4):549\u201358.","journal-title":"Ann Hematol"},{"key":"560_CR42","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","volume":"48","author":"David J. Dorer","year":"2016","unstructured":"Dorer DJ, Knickerbocker RK, Baccarani M, et al. Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016;48:84\u201391. https:\/\/doi.org\/10.1016\/j.leukres.2016.07.007.","journal-title":"Leukemia Research"},{"issue":"19","key":"560_CR43","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"J.E. Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783\u20131796. https:\/\/doi.org\/10.1056\/NEJMoa1306494.","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"560_CR44","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","volume":"17","author":"Jeffrey H Lipton","year":"2016","unstructured":"\u2022 Lipton JH, Chuah C, Guerci-Bresler A, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(5):612\u2013621. https:\/\/doi.org\/10.1016\/S1470-2045(16)00080-2. Landmark comparison of the third-generation ponatinib against the frontline imatinib","journal-title":"The Lancet Oncology"},{"key":"560_CR45","doi-asserted-by":"publisher","first-page":"6227","DOI":"10.2147\/ott.S170138","volume":"Volume 11","author":"Maher Chaar","year":"2018","unstructured":"Chaar M, Kamta J, Ait-Oudhia S. Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities. OncoTargets Ther. 2018;11:6227\u201337. https:\/\/doi.org\/10.2147\/ott.S170138.","journal-title":"OncoTargets and Therapy"},{"issue":"12","key":"560_CR46","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","volume":"110","author":"Uwe Rix","year":"2007","unstructured":"Rix U, Hantschel O, D\u00fcrnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007;110(12):4055\u20134063. https:\/\/doi.org\/10.1182\/blood-2007-07-102061.","journal-title":"Blood"},{"issue":"2","key":"560_CR47","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jaad.2014.07.032","volume":"72","author":"James B. Macdonald","year":"2015","unstructured":"Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol. 2015;72(2):203\u2013220. https:\/\/doi.org\/10.1016\/j.jaad.2014.07.032.","journal-title":"Journal of the American Academy of Dermatology"},{"key":"560_CR48","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2147\/vhrm.S108874","volume":"13","author":"N Aghel","year":"2017","unstructured":"Aghel N, Delgado DH, Lipton JH. Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance. Vasc Health Risk Manag. 2017;13:293\u2013303. https:\/\/doi.org\/10.2147\/vhrm.S108874.","journal-title":"Vasc Health Risk Manag"},{"issue":"10","key":"560_CR49","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.jacc.2015.07.025","volume":"66","author":"W Li","year":"2015","unstructured":"Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. J Am Coll Cardiol. 2015;66(10):1160\u201378. https:\/\/doi.org\/10.1016\/j.jacc.2015.07.025.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"560_CR50","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa022457.","journal-title":"N Engl J Med"},{"issue":"7","key":"560_CR51","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood-2004-01-0246","volume":"104","author":"A Pardanani","year":"2004","unstructured":"Pardanani A, Tefferi A. Imatinib targets other than bcr\/abl and their clinical relevance in myeloid disorders. Blood. 2004;104(7):1931\u20139.","journal-title":"Blood."},{"issue":"377","key":"560_CR52","doi-asserted-by":"crossref","first-page":"eaaf2584","DOI":"10.1126\/scitranslmed.aaf2584","volume":"9","author":"Arun Sharma","year":"2017","unstructured":"\u2022\u2022 Sharma A, Burridge PW, McKeithan WL, Serrano R, Shukla P, Sayed N, et al. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Sci Transl Med. 2017;9(377):eaaf2584. Novel analysis of cardiotoxic drug effects using a clinically relevant model.","journal-title":"Science Translational Medicine"},{"issue":"12","key":"560_CR53","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","volume":"110","author":"U Rix","year":"2007","unstructured":"Rix U, Hantschel O, D\u00fcrnberger G, Rix LLR, Planyavsky M, Fernbach NV, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007;110(12):4055\u201363.","journal-title":"Blood."},{"issue":"5","key":"560_CR54","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1021\/acschembio.5b01018","volume":"11","author":"FE Kwarcinski","year":"2016","unstructured":"Kwarcinski FE, Brandvold KR, Phadke S, Beleh OM, Johnson TK, Meagher JL, et al. Conformation-selective analogues of dasatinib reveal insight into kinase inhibitor binding and selectivity. ACS Chem Biol. 2016;11(5):1296\u2013304.","journal-title":"ACS Chem Biol"},{"issue":"3","key":"560_CR55","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbapap.2009.11.008","volume":"1804","author":"PW Manley","year":"2010","unstructured":"Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny-Baron G, et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta (BBA)-Proteins Proteomics. 2010;1804(3):445\u201353.","journal-title":"Biochim Biophys Acta (BBA)-Proteins Proteomics"},{"issue":"4","key":"560_CR56","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.4049\/jimmunol.1601695","volume":"199","author":"F Bellora","year":"2017","unstructured":"Bellora F, Dondero A, Corrias MV, Casu B, Regis S, Caliendo F, et al. Imatinib and nilotinib off-target effects on human NK cells, monocytes, and M2 macrophages. J Immunol. 2017;199(4):1516\u201325.","journal-title":"J Immunol"},{"issue":"3","key":"560_CR57","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/leu.2008.334","volume":"23","author":"LR Rix","year":"2009","unstructured":"Rix LR, Rix U, Colinge J, Hantschel O, Bennett K, Stranzl T, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia. 2009;23(3):477.","journal-title":"Leukemia."},{"issue":"2","key":"560_CR58","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1042\/BJ20141165","volume":"465","author":"J Ozanne","year":"2015","unstructured":"Ozanne J, Prescott AR, Clark K. The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases. Biochem J. 2015;465(2):271\u20139.","journal-title":"Biochem J"},{"issue":"1","key":"560_CR59","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/17425255.2016.1229303","volume":"13","author":"A Rowland","year":"2017","unstructured":"Rowland A, van Dyk M, Mangoni AA, Miners JO, McKinnon RA, Wiese MD, et al. Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure. Expert Opin Drug Metab Toxicol. 2017;13(1):31\u201349.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1\u20132","key":"560_CR60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2013.06.025","volume":"377","author":"L Mologni","year":"2013","unstructured":"Mologni L, Redaelli S, Morandi A, Plaza-Menacho I, Gambacorti-Passerini C. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase. Mol Cell Endocrinol. 2013;377(1\u20132):1\u20136.","journal-title":"Mol Cell Endocrinol"},{"issue":"7","key":"560_CR61","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/leu.2012.8","volume":"26","author":"E Lierman","year":"2012","unstructured":"Lierman E, Smits S, Cools J, Dewaele B, Debiec-Rychter M, Vandenberghe P. Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases. Leukemia. 2012;26(7):1693.","journal-title":"Leukemia."},{"issue":"14","key":"560_CR62","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"Brian J. Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031\u20131037. https:\/\/doi.org\/10.1056\/NEJM200104053441401.","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"560_CR63","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"Stephen G. O'Brien","year":"2003","unstructured":"O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa022457.","journal-title":"New England Journal of Medicine"},{"key":"560_CR64","doi-asserted-by":"crossref","unstructured":"Freebern WJ, Fang HS, Slade MD, Wells S, Canale J, Megill J, et al. In vitro cardiotoxicity potential comparative assessments of chronic myelogenous leukemia tyrosine kinase inhibitor therapies: dasatinib, imatinib and nilotinib. Am Soc Hematol. 2007.","DOI":"10.1182\/blood.V110.11.4582.4582"},{"issue":"10","key":"560_CR65","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1609324.","journal-title":"N Engl J Med"},{"issue":"7","key":"560_CR66","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1001\/archopht.125.7.985","volume":"125","author":"JSM Larson","year":"2007","unstructured":"Larson JSM, Bergstrom LK, Cameron JD, Erickson LA, Grimm TE. Severe periorbital edema secondary to imatinib mesylate for chronic myelogenous leukemia. JAMA Ophthalmol. 2007;125(7):985\u20136. https:\/\/doi.org\/10.1001\/archopht.125.7.985.","journal-title":"JAMA Ophthalmol"},{"issue":"20","key":"560_CR67","doi-asserted-by":"crossref","first-page":"11410","DOI":"10.1073\/pnas.96.20.11410","volume":"96","author":"R Heuchel","year":"1999","unstructured":"Heuchel R, Berg A, Tallquist M, \u00c5hl\u00e9n K, Reed RK, Rubin K, et al. Platelet-derived growth factor \u03b2 receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3\u2032 kinase signaling. Proc Natl Acad Sci. 1999;96(20):11410\u20135.","journal-title":"Proc Natl Acad Sci"},{"issue":"7","key":"560_CR68","first-page":"2929","volume":"61","author":"K Pietras","year":"2001","unstructured":"Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK, Heldin CH, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001;61(7):2929\u201334.","journal-title":"Cancer Res"},{"issue":"9","key":"560_CR69","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/rccm.201301-0136LE","volume":"188","author":"J Aman","year":"2013","unstructured":"Aman J, Peters MJ, Weenink C, van Nieuw Amerongen GP, Vonk NA. Reversal of vascular leak with imatinib. Am J Respir Crit Care Med. 2013;188(9):1171\u20133.","journal-title":"Am J Respir Crit Care Med"},{"issue":"23","key":"560_CR70","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1161\/circulationaha.112.134304","volume":"126","author":"J Aman","year":"2012","unstructured":"Aman J, van Bezu J, Damanafshan A, Huveneers S, Eringa EC, Vogel SM, et al. Effective treatment of edema and endothelial barrier dysfunction with imatinib. Circulation. 2012;126(23):2728\u201338. https:\/\/doi.org\/10.1161\/circulationaha.112.134304.","journal-title":"Circulation."},{"issue":"24","key":"560_CR71","doi-asserted-by":"crossref","first-page":"e691","DOI":"10.1200\/JCO.2011.35.6733","volume":"29","author":"Fabrizio Carnevale-Schianca","year":"2011","unstructured":"Carnevale-Schianca F, Gallo S, Rota-Scalabrini D, et al. Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin's lymphoma: hope for severe chemotherapy-induced toxicity?. J Clin Oncol. 2011;29(24):e691\u2013e693.","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"560_CR72","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nm1787","volume":"14","author":"EJ Su","year":"2008","unstructured":"Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J, et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med. 2008;14(7):731.","journal-title":"Nat Med"},{"issue":"7323","key":"560_CR73","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature09522","volume":"468","author":"A Armulik","year":"2010","unstructured":"Armulik A, Genov\u00e9 G, M\u00e4e M, Nisancioglu MH, Wallgard E, Niaudet C, et al. Pericytes regulate the blood\u2013brain barrier. Nature. 2010;468(7323):557.","journal-title":"Nature."},{"issue":"1","key":"560_CR74","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1183\/09031936.00054407","volume":"32","author":"MJ Overbeek","year":"2008","unstructured":"Overbeek MJ, van Nieuw Amerongen GP, Boonstra A, Smit EF, Vonk-Noordegraaf A. Possible role of imatinib in clinical pulmonary veno-occlusive disease. Eur Respir J. 2008;32(1):232\u20135. https:\/\/doi.org\/10.1183\/09031936.00054407.","journal-title":"Eur Respir J"},{"issue":"8","key":"560_CR75","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/nm1446","volume":"12","author":"R Kerkela","year":"2006","unstructured":"Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12(8):908\u201316. https:\/\/doi.org\/10.1038\/nm1446.","journal-title":"Nat Med"},{"issue":"9","key":"560_CR76","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.leukres.2010.01.004","volume":"34","author":"A Wolf","year":"2010","unstructured":"Wolf A, Couttet P, Dong M, Grenet O, Heron M, Junker U, et al. Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies. Leuk Res. 2010;34(9):1180\u20138.","journal-title":"Leuk Res"},{"issue":"1","key":"560_CR77","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nm0107-15a","volume":"13","author":"G Rosti","year":"2007","unstructured":"Rosti G, Martinelli G, Baccarani M. In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate\u2019. Nat Med. 2007;13(1):15; author reply \u22126. https:\/\/doi.org\/10.1038\/nm0107-15a.","journal-title":"Nat Med"},{"issue":"1","key":"560_CR78","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/nm0107-14","volume":"13","author":"E Atallah","year":"2007","unstructured":"Atallah E, Kantarjian H, Cortes J. In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate\u2019. Nat Med. 2007;13(1):14; author reply 5\u20136. https:\/\/doi.org\/10.1038\/nm0107-14.","journal-title":"Nat Med"},{"issue":"1","key":"560_CR79","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/toxsci\/kfs192","volume":"129","author":"Wenyue Hu","year":"2012","unstructured":"Hu W, Lu S, McAlpine I, et al. Mechanistic investigation of imatinib-induced cardiac toxicity and the involvement of c-Abl kinase. Toxicol Sci. 2012;129(1):188\u2013199. https:\/\/doi.org\/10.1093\/toxsci\/kfs192.","journal-title":"Toxicological Sciences"},{"issue":"24","key":"560_CR80","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1161\/01.CIR.0000039105.49749.6F","volume":"106","author":"DM Lloyd-Jones","year":"2002","unstructured":"Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D\u2019Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106(24):3068\u201372.","journal-title":"Circulation."},{"issue":"3","key":"560_CR81","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1078155210378913","volume":"17","author":"NM Agostino","year":"2011","unstructured":"Agostino NM, Chinchilli VM, Lynch CJ, Koszyk-Szewczyk A, Gingrich R, Sivik J, et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract. 2011;17(3):197\u2013202.","journal-title":"J Oncol Pharm Pract"},{"issue":"6b","key":"560_CR82","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/j.1582-4934.2009.00902.x","volume":"14","author":"ML Ballinger","year":"2010","unstructured":"Ballinger ML, Osman N, Hashimura K, de Haan JB, Jandeleit-Dahm K, Allen T, et al. Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo. J Cell Mol Med. 2010;14(6b):1408\u201318.","journal-title":"J Cell Mol Med"},{"key":"560_CR83","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.5551\/jat.8730","volume":"18","author":"S Masuda","year":"2011","unstructured":"Masuda S, Nakano K, Funakoshi K, Zhao G, Meng W, Kimura S, et al. Imatinib mesylate-incorporated nanoparticle-eluting stent attenuates in-stent neointimal formation in porcine coronary arteries. J Atheroscler Thromb. 2011;18:1043\u201353.","journal-title":"J Atheroscler Thromb"},{"issue":"6","key":"560_CR84","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/leu.2013.69","volume":"27","author":"F J Giles","year":"2013","unstructured":"Giles FJ, Mauro MJ, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013;27(6):1310\u20131315. https:\/\/doi.org\/10.1038\/leu.2013.69.","journal-title":"Leukemia"},{"issue":"11","key":"560_CR85","doi-asserted-by":"publisher","first-page":"L1294","DOI":"10.1152\/ajplung.00031.2015","volume":"309","author":"Alicia N. Rizzo","year":"2015","unstructured":"Rizzo AN, Sammani S, Esquinca AE, et al. Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2015;309(11):L1294\u2013L1304. https:\/\/doi.org\/10.1152\/ajplung.00031.2015.","journal-title":"American Journal of Physiology-Lung Cellular and Molecular Physiology"},{"issue":"12","key":"560_CR86","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","volume":"94","author":"E Weisberg","year":"2006","unstructured":"Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006;94(12):1765.","journal-title":"Br J Cancer"},{"issue":"24","key":"560_CR87","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"Giuseppe Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251\u20132259. https:\/\/doi.org\/10.1056\/NEJMoa0912614.","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"560_CR88","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/ajh.22037","volume":"86","author":"Karl J. Aichberger","year":"2011","unstructured":"Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86(7):533\u2013539. https:\/\/doi.org\/10.1002\/ajh.22037.","journal-title":"American Journal of Hematology"},{"issue":"5","key":"560_CR89","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044\u20131054. https:\/\/doi.org\/10.1038\/leu.2016.5.","journal-title":"Leukemia"},{"issue":"12","key":"560_CR90","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.clml.2017.07.006","volume":"17","author":"N Aghel","year":"2017","unstructured":"Aghel N, Lipton JH, Atenafu EG, Kim DDH, Delgado DH. Cardiovascular events after exposure to nilotinib in chronic myeloid leukemia: long-term follow-up. Clin Lymphoma Myeloma Leuk. 2017;17(12):870\u20138. e1.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"560_CR91","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1038\/s41375-018-0337-0","volume":"33","author":"Soban Sadiq","year":"2019","unstructured":"Sadiq S, Owen E, Foster T, et al. Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts. Leukemia. 2019;33(7):1810\u20131814. https:\/\/doi.org\/10.1038\/s41375-018-0337-0.","journal-title":"Leukemia"},{"key":"560_CR92","doi-asserted-by":"publisher","unstructured":"Bocchia M, Galimberti S, Aprile L, et al. Genetic predisposition and induced pro-inflammatory\/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients. Oncotarget. 2016;7(44):72311\u201372321. https:\/\/doi.org\/10.18632\/oncotarget.11100.","DOI":"10.18632\/oncotarget.11100"},{"key":"560_CR93","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.thromres.2016.07.019","volume":"145","author":"Naif Alhawiti","year":"2016","unstructured":"Alhawiti N, Burbury KL, Kwa FA, et al. The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state. Thromb Res. 2016;145:54\u201364. https:\/\/doi.org\/10.1016\/j.thromres.2016.07.019.","journal-title":"Thrombosis Research"},{"key":"560_CR94","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.leukres.2017.05.005","volume":"58","author":"Masumi Sukegawa","year":"2017","unstructured":"Sukegawa M, Wang X, Nishioka C, et al. The BCR\/ABL tyrosine kinase inhibitor, nilotinib, stimulates expression of IL-1\u03b2 in vascular endothelium in association with downregulation of miR-3p.\u00a0Leuk Res. 2017;58:83\u201390. https:\/\/doi.org\/10.1016\/j.leukres.2017.05.005.","journal-title":"Leukemia Research"},{"issue":"11","key":"560_CR95","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1038\/leu.2017.245","volume":"31","author":"E Hadzijusufovic","year":"2017","unstructured":"Hadzijusufovic E, Albrecht-Schgoer K, Huber K, et al. Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site. Leukemia. 2017;31(11):2388\u20132397. https:\/\/doi.org\/10.1038\/leu.2017.245.","journal-title":"Leukemia"},{"issue":"5","key":"560_CR96","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.leukres.2010.11.001","volume":"35","author":"Armin Wolf","year":"2011","unstructured":"Wolf A, Couttet P, Dong M, et al. Preclinical evaluation of potential nilotinib cardiotoxicity. Leuk Res. 2011;35(5):631\u2013637. https:\/\/doi.org\/10.1016\/j.leukres.2010.11.001.","journal-title":"Leukemia Research"},{"issue":"27","key":"560_CR97","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"LJ Lombardo","year":"2004","unstructured":"Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47(27):6658\u201361. https:\/\/doi.org\/10.1021\/jm049486a.","journal-title":"J Med Chem"},{"issue":"25","key":"560_CR98","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","volume":"25","author":"Alfonso Quint\u00e1s-Cardama","year":"2007","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, O'brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25(25):3908\u20133914. https:\/\/doi.org\/10.1200\/JCO.2007.12.0329.","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"560_CR99","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.clml.2016.09.012","volume":"17","author":"Jorge E. Cortes","year":"2017","unstructured":"Cortes JE, Jimenez CA, Mauro MJ, Geyer A, Pinilla-Ibarz J, Smith BD. Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management. Clin Lymphoma Myeloma Leuk. 2017;17(2):78\u201382. https:\/\/doi.org\/10.1016\/j.clml.2016.09.012.","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"issue":"5","key":"560_CR100","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","volume":"141","author":"Hugues de Lavallade","year":"2008","unstructured":"de Lavallade H, Punnialingam S, Milojkovic D, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol. 2008;141(5):745\u2013747. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07108.x.","journal-title":"British Journal of Haematology"},{"issue":"5","key":"560_CR101","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s12185-010-0565-1","volume":"91","author":"Yasunobu Nagata","year":"2010","unstructured":"Nagata Y, Ohashi K, Fukuda S, Kamata N, Akiyama H, Sakamaki H. Clinical features of dasatinib-induced large granular lymphocytNagataosis and pleural effusion. Int J Hematol. 2010;91(5):799\u2013807. https:\/\/doi.org\/10.1007\/s12185-010-0565-1.","journal-title":"International Journal of Hematology"},{"issue":"4","key":"560_CR102","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/cam4.1019","volume":"6","author":"Swapan K. Dasgupta","year":"2017","unstructured":"Dasgupta SK, Le A, Vijayan KV, Thiagarajan P. Dasatinib inhibits actin fiber reorganization and promotes endothelial cell permeability through RhoA-ROCK pathway. Cancer Med. 2017;6(4):809\u2013818. https:\/\/doi.org\/10.1002\/cam4.1019.","journal-title":"Cancer Medicine"},{"issue":"1","key":"560_CR103","doi-asserted-by":"crossref","first-page":"1701096","DOI":"10.1183\/13993003.01096-2017","volume":"51","author":"C Phan","year":"2018","unstructured":"Phan C, Jutant E-M, Tu L, Thuillet R, Seferian A, Montani D, et al. Dasatinib increases endothelial permeability leading to pleural effusion. Eur Respir J. 2018;51(1):1701096.","journal-title":"Eur Respir J"},{"issue":"25","key":"560_CR104","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1182\/blood-2013-03-491423","volume":"122","author":"J Han","year":"2013","unstructured":"Han J, Zhang G, Welch EJ, Liang Y, Fu J, Vogel SM, et al. A critical role for Lyn kinase in strengthening endothelial integrity and barrier function. Blood. 2013;122(25):4140\u20139.","journal-title":"Blood."},{"issue":"17","key":"560_CR105","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","volume":"125","author":"David Montani","year":"2012","unstructured":"Montani D, Bergot E, G\u00fcnther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128\u20132137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.079921.","journal-title":"Circulation"},{"issue":"1","key":"560_CR106","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1183\/09031936.00092306","volume":"30","author":"A. J. Peacock","year":"2007","unstructured":"Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007;30(1):104\u2013109. https:\/\/doi.org\/10.1183\/09031936.00092306.","journal-title":"European Respiratory Journal"},{"issue":"115","key":"560_CR107","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1183\/09059180.00007309","volume":"19","author":"M. Humbert","year":"2010","unstructured":"Humbert M. Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology. Eur Respir Rev. 2010;19(115):59\u201363. https:\/\/doi.org\/10.1183\/09059180.00007309.","journal-title":"European Respiratory Review"},{"issue":"18","key":"560_CR108","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1016\/j.jacc.2015.03.540","volume":"65","author":"Vallerie V. McLaughlin","year":"2015","unstructured":"McLaughlin VV, Shah SJ, Souza R, Humbert M. Management of pulmonary arterial hypertension. J Am Coll Cardiol. 2015;65(18):1976\u20131997. https:\/\/doi.org\/10.1016\/j.jacc.2015.03.540.","journal-title":"Journal of the American College of Cardiology"},{"key":"560_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/791231","volume":"2013","author":"I-Ta Lee","year":"2013","unstructured":"Lee IT, Yang CM. Inflammatory signalings involved in airway and pulmonary diseases. Mediators Inflamm. 2013;2013:791231. https:\/\/doi.org\/10.1155\/2013\/791231.","journal-title":"Mediators of Inflammation"},{"issue":"9","key":"560_CR110","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1172\/JCI86249","volume":"126","author":"C Guignabert","year":"2016","unstructured":"Guignabert C, Phan C, Seferian A, Huertas A, Tu L, Thuillet R, et al. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest. 2016;126(9):3207\u201318.","journal-title":"J Clin Invest"},{"key":"560_CR111","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3389\/fphys.2018.00537","volume":"9","author":"C Fazakas","year":"2018","unstructured":"Fazakas C, Nagaraj C, Zabini D, V\u00e9gh AG, Marsh LM, Wilhelm I, et al. Rho-kinase inhibition ameliorates dasatinib-induced endothelial dysfunction and pulmonary hypertension. Front Physiol. 2018;9:537.","journal-title":"Front Physiol"},{"issue":"17","key":"560_CR112","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","volume":"125","author":"D Montani","year":"2012","unstructured":"Montani D, Bergot E, G\u00fcnther S, Savale L, Bergeron A, Bourdin A, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128\u201337.","journal-title":"Circulation."},{"issue":"4","key":"560_CR113","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00280-017-3264-2","volume":"79","author":"Bethany Baumgart","year":"2017","unstructured":"Baumgart B, Guha M, Hennan J, et al. In vitro and in vivo evaluation of dasatinib and imatinib on physiological parameters of pulmonary arterial hypertension. Cancer Chemother Pharmacol. 2017;79(4):711\u2013723. https:\/\/doi.org\/10.1007\/s00280-017-3264-2.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"23","key":"560_CR114","doi-asserted-by":"publisher","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","volume":"66","author":"M. Puttini","year":"2006","unstructured":"Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006;66(23):11314\u201311322. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-1199.","journal-title":"Cancer Research"},{"issue":"6","key":"560_CR115","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1080\/10428194.2016.1239258","volume":"58","author":"A Gover-Proaktor","year":"2017","unstructured":"Gover-Proaktor A, Granot G, Shapira S, Raz O, Pasvolsky O, Nagler A, et al. Ponatinib reduces viability, migration, and functionality of human endothelial cells. Leuk Lymphoma. 2017;58(6):1455\u201367. https:\/\/doi.org\/10.1080\/10428194.2016.1239258.","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"560_CR116","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1182\/bloodadvances.2018020396","volume":"2","author":"Srila Gopal","year":"2018","unstructured":"Gopal S, Lu Q, Man JJ, Baur W, Rao SP, Litichevskiy L, et al. A phosphoproteomic signature in endothelial cells predicts vascular toxicity of tyrosine kinase inhibitors used in CML. Blood Adv. 2018;2(14):1680\u20134. https:\/\/doi.org\/10.1182\/bloodadvances.2018020396.","journal-title":"Blood Advances"},{"issue":"5","key":"560_CR117","doi-asserted-by":"publisher","first-page":"e0196559","DOI":"10.1371\/journal.pone.0196559","volume":"13","author":"Peter J. Wermuth","year":"2018","unstructured":"Wermuth PJ, Jimenez SA. Abrogation of transforming growth factor-\u03b2-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib).\u00a0PLoS One. 2018;13(5):e0196559. Published 2018 May 2. https:\/\/doi.org\/10.1371\/journal.pone.0196559.","journal-title":"PLOS ONE"},{"key":"560_CR118","doi-asserted-by":"publisher","unstructured":"Carneiro PJ, Clevelario AL, Padilha GA, et al. Bosutinib Therapy Ameliorates Lung Inflammation and Fibrosis in Experimental Silicosis. Front Physiol. 2017;8:159. Published 2017 Mar 15. https:\/\/doi.org\/10.3389\/fphys.2017.00159.","DOI":"10.3389\/fphys.2017.00159"},{"issue":"2","key":"560_CR119","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1042\/bj20141165","volume":"465","author":"J Ozanne","year":"2015","unstructured":"Ozanne J, Prescott AR, Clark K. The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases. Biochem J. 2015;465(2):271\u20139. https:\/\/doi.org\/10.1042\/bj20141165.","journal-title":"Biochem J"},{"issue":"5","key":"560_CR120","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"Thomas O'Hare","year":"2009","unstructured":"O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401\u2013412. https:\/\/doi.org\/10.1016\/j.ccr.2009.09.028.","journal-title":"Cancer Cell"},{"issue":"14","key":"560_CR121","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1182\/blood-2018-10-881557","volume":"133","author":"Yllka Latifi","year":"2019","unstructured":"Latifi Y, Moccetti F, Wu M, et al. Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. Blood. 2019;133(14):1597\u20131606. https:\/\/doi.org\/10.1182\/blood-2018-10-881557.","journal-title":"Blood"},{"issue":"1","key":"560_CR122","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.thromres.2014.11.009","volume":"135","author":"Cassandra P. Loren","year":"2015","unstructured":"Loren CP, Aslan JE, Rigg RA, et al. The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear. Thromb Res. 2015;135(1):155\u2013160. https:\/\/doi.org\/10.1016\/j.thromres.2014.11.009.","journal-title":"Thrombosis Research"},{"key":"560_CR123","doi-asserted-by":"crossref","unstructured":"Pouwer MG, Pieterman EJ, Verschuren L, et al. The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model. Front Cardiovasc Med. 2018;5:55. Published 2018 Jun 12.","DOI":"10.3389\/fcvm.2018.00055"},{"issue":"20","key":"560_CR124","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1016\/j.jacc.2017.09.1095","volume":"70","author":"HM Chang","year":"2017","unstructured":"Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 2. J Am Coll Cardiol. 2017;70(20):2552\u201365. https:\/\/doi.org\/10.1016\/j.jacc.2017.09.1095.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"560_CR125","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1161\/HYPERTENSIONAHA.117.08856","volume":"70","author":"RM Touyz","year":"2017","unstructured":"Touyz RM, Lang NN, Herrmann J, Van Den Meiracker AH, Danser AJ. Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition. Hypertension. 2017;70(2):220\u20136.","journal-title":"Hypertension."},{"issue":"1","key":"560_CR126","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/10428194.2018.1466294","volume":"60","author":"Ayala Gover-Proaktor","year":"2018","unstructured":"Gover-Proaktor A, Granot G, Pasmanik-Chor M, et al. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells. Leuk Lymphoma. 2019;60(1):189\u2013199. https:\/\/doi.org\/10.1080\/10428194.2018.1466294.","journal-title":"Leukemia & Lymphoma"},{"key":"560_CR127","doi-asserted-by":"publisher","unstructured":"Paez-Mayorga J, Chen AL, Kotla S, et al. Ponatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylation. Front Cardiovasc Med. 2018;5:125. Published 2018 Sep 6. https:\/\/doi.org\/10.3389\/fcvm.2018.00125.","DOI":"10.3389\/fcvm.2018.00125"},{"issue":"5","key":"560_CR128","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/cvr\/cvz006","volume":"115","author":"Anand P Singh","year":"2019","unstructured":"Singh AP, Glennon MS, Umbarkar P, Gupte M, Galindo CL, Zhang Q, et al. Ponatinib-induced cardiotoxicity: delineating the signaling mechanisms and potential rescue strategies. Cardiovasc Res. 2019;115(5):966\u201377. https:\/\/doi.org\/10.1093\/cvr\/cvz006.","journal-title":"Cardiovascular Research"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-020-00560-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-020-00560-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-020-00560-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T19:57:51Z","timestamp":1613764671000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-020-00560-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":128,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["560"],"URL":"https:\/\/doi.org\/10.1007\/s11899-020-00560-x","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"20 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethics Guidelines"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}